EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.
Missing: Erydel's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Erydel's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Erydel
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Erydel is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Erydel has filed 1 patent.
Vascular diseases, Red blood cell disorders, Blood tests, Clusters of differentiation, Rare diseases
Vascular diseases, Red blood cell disorders, Blood tests, Clusters of differentiation, Rare diseases
Latest Erydel News
Oct 28, 2021
EryDel Announces Top-line Results from Phase 3 ATTeST Trial You are here EryDel Announces Top-line Results from Phase 3 ATTeST Trial BRESSO, JULY 12th 2021 – EryDel SpA, a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology announced today topline results from its Phase 3 ATTeST clinical trial in patients with Ataxia Telangiectasia (AT), a devastating neurological disease for which there is no approved therapy. The ATTeST trial was a pivotal multicenter, double-blind and placebo-controlled study conducted in the United States, Europe, Asia, Australia and Africa. 175 patients age 6 and above with AT were enrolled and randomized to either high or low dose of EryDex or placebo treatment in a 1:1:1 ratio. The treatment duration was 6 months for the efficacy and extended to 12 months for long term safety assessment. The primary endpoint was the change of the modified International Cooperative Ataxia Rating Scale (mICARS), for the ex-US and the Rescored mICARS (RmICARS) for the US, from baseline to month 6 compared to placebo. The pre-specified ITT analysis of patients age 6 to 9 (N= 88) showed statistically significant differences vs. placebo for the primary endpoint (mICARS p=0.020 and RmICARS p=0.025). These results were also supported by analysis of the key secondary end point, the clinical global impression of change (CGI-C, p=0.04), and a patient self-assessment of quality of life as measured on the visual analogue scale of the EuroQol Instrument further supported the meaningfulness of this Improvement. The 6-month safety analysis (which is also including safety information of patients who have, at time of database lock, completed up to months 12) showed that EryDex is well tolerated and did not identify any alarming safety signals that might be expected with chronic steroid use as confirmed by an Independent Data Safety Monitoring Board. “The findings of the ATTeST study for the younger patients open, for the first time ever, the door to an effective and safe treatment for our AT patients. This is a very promising outcome for the whole AT community, which had been without any viable treatment option so far” commented Howard Lederman, MD, PhD, Professor of Pediatrics, Medicine and Pathology at the Johns Hopkins University School of Medicine and Principal Investigator of the ATTeST study at the Johns Hopkins Hospital in Baltimore. Dr. Stefan Zielen, Professor of Allergology, Pneumology and Mucoviscidosis and Principal Investigator at the Department for Children and Adolescents, Goethe University of Frankfurt, Germany added “Ataxia Telangiectasia is a devastating disease starting in early childhood that is affecting patients around the world with no perspective for meaningful therapeutic intervention. Natural history data shows that it is progressing rapidly particularly in children under age 10. These results suggest a remarkable slowing done of this progression and mean new hope for improving the lives of our patients and their families”. Guenter R Janhofer, MD, PhD, Chief Medical Officer of EryDel, concluded from these findings that “the statistically significant and clinically meaningful efficacy results for EryDex in Ataxia Telangiectasia offer, for the first time, hope to patients and caregivers affected by AT. After completion of analysis of the 12-month safety data EryDel will engage with the FDA to agree on the next steps for preparing a New Drug Application (NDA), followed by regulatory submissions in Europe and selected other countries”. About Ataxia Telangiectasia (AT) Ataxia Telangiectasia is a rare genetic disease caused by biallelic mutations in the ataxia telangiectasia mutated (ATM) gene, for which no established therapy is currently available. The major clinical feature of AT is severe progressive neurodegeneration from early infancy. Specific features include progressive ataxia of the trunk and limbs, involuntary movements, oculomotor apraxia, difficulties with speech and swallowing, immunodeficiency with recurrent respiratory tract infections, radiosensitivity and an increased incidence of cancer. About EryDel EryDel SpA is a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology. Its most advanced product, EryDex, is under late stage development for the treatment of Ataxia Telangiectasia, a rare autosomal recessive disorder for which no established therapy is currently available. EryDex is an automated outpatient bedside technology to ex-vivo encapsulate dexamethasone sodium phosphate (DSP; an inactive pro-drug) into patient’s red blood cells, which are then re-infused, allowing the slow release in circulation of low doses of dexamethasone (active drug) over a month. EryDex has received Orphan Drug designation for the treatment of AT both from the FDA and the EMA. An international multicenter, Phase 3 pivotal study, ATTeST, has been successfully completed and regulatory filing is under preparation. The ATTeST project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 667946. Posted on 12 Jul 2021 EryDel Search Topics
Erydel Web Traffic
Erydel Frequently Asked Questions (FAQ)
When was Erydel founded?
Erydel was founded in 2007.
Where is Erydel's headquarters?
Erydel's headquarters is located at 36 Via Sasso, Urbino.
What is Erydel's latest funding round?
Erydel's latest funding round is Unattributed.
How much did Erydel raise?
Erydel raised a total of $67.72M.
Who are the investors of Erydel?
Investors of Erydel include European Investment Bank, Innogest Capital, Genextra and Sofinnova Partners.
Who are Erydel's competitors?
Competitors of Erydel include Brainsgate, PolyPid, MicroCHIPS Biotech, MediQuest Therapeutics, Savara, MonoSol Rx, Cellnovo, Carbylan Therapeutics, Capnia, Transcept Pharmaceuticals and 28 more.
Compare Erydel to Competitors
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
Vascular is driving innovation in vascular access medical technology. The company's passion is uncomplicating venous access, chemotherapy, and drug delivery. The company's product designs offer rapid exchange, Biomimetic coating, power injection ability, and associated improvements that help the company's catheters remain patent and effective. Learn more about how the company's products can improve patient care through reduced complications, while delivering lower overall costs for access and drug delivery.
Global Protein Products (GPP) is a zein protein coatings company. Zein protein is the storage protein in corn kernels. It has excellent film-forming and thermoplastic characteristics.
MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.
Next Breath, LLC is a contract pharmaceutical research and development organization dedicated to pre-clinical identification and evaluation of commercially viable respiratory and nasal drug delivery platforms. NB's business will discover and exploit optimal drug and delivery device combinations that will increase the company's partners' probability of success when their products advance into human clinical trials and the marketplace. Next Breath seeks to meet the pharmaceutical industry's outsourcing needs and to provide intellectual expertise to biotechnology companies that are developing inhalation products.
Kucera Pharmaceutical Company is based in Winston-Salem, NC. The company started with a drug delivery approach that combined or conjugated delivery molecules with therapeutic molecules as a platform technology, both to improve the properties of the attached therapeutic molecules (making them orally available and improving distribution) and to extend patent life.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.